BTG upbeat as full year profit rises

International specialist healthcare firm BTG posted a robust set of annual figures following a strong performance in its specialty pharmaceuticals business, increased royalties from licensed products and after it moved to direct sales of its interventional oncology products in the US.

International specialist healthcare firm BTG posted a robust set of annual figures following a strong performance in its specialty pharmaceuticals business, increased royalties from licensed products and after it moved to direct sales of its interventional oncology products in the US.

The group, which develops and sells products targeting critical care, cancer and varicose veins, said revenue increased by 19% to £233.7m for the year ended March 31st 2013 while underlying operating profit before acquisition adjustments and reorganisation costs rose to £69.0m from £54.0m a year earlier. Reported operating profit increased to £25.7m from £19.9m.

Chief Executive Officer Louise Makin said the results reflect the successful transition of its business into a commercially focused, specialist healthcare company that makes and markets its own products.

Specialty Pharmaceuticals revenue grew 27% to £97.2m over the year, helped by the first full year of commercial sales from Voraxaze and to strong performances from both CroFab and DigiFab, with the latter benefitting from geographic expansion and a price increase.

Makin added: "We are on track with our growth strategy, and are investing in our Beads business, preparing for a potential H1 2014 US approval and launch of Varisolve and actively seeking opportunities to add new products and programmes. Overall, we have the financial resources and capabilities to continue to build the business and deliver our growth strategy."

The group generated cash of £46.8m, with cash and cash equivalents, together with cash on fixed term deposits, of £158.7m at March 31st 2013 compared to £111.9m the same time a year earlier.

Looking ahead BTG said: "Overall, the business is in good shape: we have the financial resources, capabilities and opportunities to enable us to continue building value and to deliver further profitable growth."

CJ

Recommended

Share tips of the week – 21 January
Share tips

Share tips of the week – 21 January

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
21 Jan 2022
Seven cheap defence stocks to buy now
Share tips

Seven cheap defence stocks to buy now

We’ve got used to a world without war between major powers, but that era is coming to an end as Russia threatens Ukraine and China eyes Taiwan. Buy de…
21 Jan 2022
Invest in VCTs: tax-free investments set to break records
Investment strategy

Invest in VCTs: tax-free investments set to break records

Generous tax breaks make VCTs – venture capital funds – an attractive supplement to pensions.
21 Jan 2022
HubSpot: a tech stock set to tumble
Trading

HubSpot: a tech stock set to tumble

US tech stocks have had a fantastic couple of years. But this year is unlikely to be so bullish for high-fliers that can’t turn big profits.
18 Jan 2022

Most Popular

Ask for a pay rise – everyone else is
Inflation

Ask for a pay rise – everyone else is

As inflation bites and the labour market remains tight, many of the nation's employees are asking for a pay rise. Merryn Somerset Webb explains why yo…
17 Jan 2022
Temple Bar’s Ian Lance and Nick Purves: the essence of value investing
Investment strategy

Temple Bar’s Ian Lance and Nick Purves: the essence of value investing

Ian Lance and Nick Purves of the Temple Bar investment trust explain the essence of “value investing” – buying something for less than its intrinsic v…
14 Jan 2022
Interest rates might rise faster than expected – what does that mean for your money?
Global Economy

Interest rates might rise faster than expected – what does that mean for your money?

The idea that the US Federal Reserve could raise interest rates much earlier than anticipated has upset the markets. John Stepek explains why, and wha…
6 Jan 2022